Thymus Gland Data Links Organ Health to Lower Mortality Rates
Data from recent immunological research published in scientific journals reveals that the thymus gland behind the breastbone—long considered largely functionless in adulthood—correlates strongly with overall human longevity and immune health. According to findings from Mass General Brigham, adults with high thymus health face a roughly 50 percent lower all-cause mortality risk compared to those with low organ health. The large-scale National Lung Screening Trial evaluated more than 25,000 adults to establish these baseline health metrics. Researchers adjusted their statistical models to account for age and smoking history.
Cardiovascular and Cancer Risks Decline With High Organ Scores
Specific cause-of-mortality figures from the Mass General Brigham investigation highlight distinct clinical protections linked to the thymus. Patients exhibiting high thymus health demonstrated a 63 percent lower risk of cardiovascular death. Concurrently, their risk of lung cancer dropped by 36 percent.
Additional evaluations from a cohort of more than 2,500 participants in the Framingham Heart Study reinforce these structural correlations. Within a subset of over 1,200 patients undergoing immunotherapy, high thymus health connected to a 37 percent lower risk of disease progression. That same group experienced a 44 percent reduction in mortality risk during treatment. Researchers caution, however, that the specific CT score used for these evaluations is not yet ready for regular routine clinical care. Current studies provide no evidence that specific lifestyle changes can halt the natural aging process of the thymus gland.
Complementing the primary CT evaluations, an artificial intelligence-driven thymus health score derived from computed tomography scans similarly correlates with lower mortality rates, particularly regarding cardiovascular events and lung cancer. Surgical practices reflect these findings. Observations published in the New England Journal of Medicine demonstrated that complete surgical removal of the thymus gland increases both mortality and cancer risks. Consequently, the preservation of the organ is recommended during surgical interventions. Clinical observations also suggest that a high body-mass index, smoking, and chronic inflammation accelerate tissue involution, whereas physical activity may slow down this structural degradation.
Experimental Immunotherapy Combinations Target Aging Immune Systems
While diagnostic scoring advances, experimental trials are actively exploring ways to restore immune function. The TRIIM-X study project tests a specific combination of hormones and medications designed to support immune restoration. Concurrently, researchers at the Massachusetts Institute of Technology have rejuvenated the immune systems of older mice by using reprogrammed liver cells. Another primary focus centers on the hormone thymulin, whose natural internal levels decline steadily with age. A study published in Nature Communications details connections between thymulin, inflammatory pathways, cancer progression, and responses to immunotherapy. Building on this foundation, Fumito Ito and a research team at the Keck School of Medicine of the University of Southern California secured funding from the National Institutes of Health. These researchers plan trials on older mice with breast cancer or melanomas to analyze thymulin as a potential complement to existing anti-PD-1 and anti-PD-L1 therapies against metastatic tumors. Clinical efficacy for this combination in human patients remains unproven.
Worth a look